ASCIL Biopharm

APOC new treatment for NET and Acromegaly

Biodrugs/ Drugs
Cancer
APOC is a new drug product containing octreotide, the best in class somatostatin analogue (SSA) and the cornerstone of therapy for patients with Neuroendocrine Tumors (NETs) and acromegaly. ASCIL is selecting partner(s) for pivotal phase III studies.
2Phase II, 1Phase I, 2Regulatory Preclinical, 1Non Regulatory Preclinical